MeSH term | MeSH ID | Detail |
---|---|---|
Hemorrhagic Septicemia, Viral | D031941 | 1 associated lipids |
Steatorrhea | D045602 | 2 associated lipids |
Micronuclei, Chromosome-Defective | D048629 | 33 associated lipids |
Atherosclerosis | D050197 | 85 associated lipids |
(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Javelle E et al. | Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. | 2011 | Vaccine | pmid:21172376 |
Montagnani S et al. | Autoimmune hemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases. | 2011 | Ann Pharmacother | pmid:21189364 |
Esposito S et al. | Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. | 2011 | Vaccine | pmid:21199699 |
Lopez P et al. | Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. | 2011 | J. Infect. Dis. | pmid:21606530 |
Cen-Pacheco F et al. | Cytotoxic oxasqualenoids from the red alga Laurencia viridis. | 2011 | Eur J Med Chem | pmid:21616566 |
Raouane M et al. | Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. | 2011 | J. Med. Chem. | pmid:21561161 |
Nowosielski M and Hoffmann M | Do the substituent effects affect conformational freedom of squalene in hopene biosynthesis? | 2011 | J Mol Model | pmid:21562825 |
Hernández-GarcÃa I et al. | [Adverse events after administration of A/H1N1 vaccine to patients]. | 2011 | Med Clin (Barc) | pmid:20199781 |
Fabbiani M et al. | Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. | 2011 | Vaccine | pmid:21349364 |
Gill S et al. | Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. | 2011 | Cell Metab. | pmid:21356516 |
Kaya K et al. | Thraustochytrid Aurantiochytrium sp. 18W-13a accummulates high amounts of squalene. | 2011 | Biosci. Biotechnol. Biochem. | pmid:22056449 |
Celia C et al. | Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. | 2011 | Expert Opin Drug Deliv | pmid:22077480 |
Brito LA et al. | An alternative renewable source of squalene for use in emulsion adjuvants. | 2011 | Vaccine | pmid:21723355 |
Wu J et al. | Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. | 2011 | Arch. Virol. | pmid:21110049 |
Packwood DM and Phillips LF | A stochastic, local mode study of neon-liquid surface collision dynamics. | 2011 | Phys Chem Chem Phys | pmid:21042647 |
Andrews N et al. | Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. | 2011 | J. Infect. Dis. | pmid:21148494 |
Kajaste-Rudnitski A et al. | Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. | 2011 | AIDS | pmid:21150561 |
Inagaki YS et al. | Investigation of the potential for triterpene synthesis in rice through genome mining and metabolic engineering. | 2011 | New Phytol. | pmid:21501172 |
Garcia-Sicilia J et al. | Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. | 2011 | Vaccine | pmid:21504774 |
O'Hagan DT et al. | MF59 adjuvant: the best insurance against influenza strain diversity. | 2011 | Expert Rev Vaccines | pmid:21506643 |
Esposito S et al. | Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. | 2011 | Hum Vaccin | pmid:21508673 |
AÄimoviÄ J et al. | Circadian rhythm of cholesterol synthesis in mouse liver: a statistical analysis of the post-squalene metabolites in wild-type and Crem-knock-out mice. | 2011 | Biochem. Biophys. Res. Commun. | pmid:21531203 |
Siedenburg G and Jendrossek D | Squalene-hopene cyclases. | 2011 | Appl. Environ. Microbiol. | pmid:21531832 |
Tsai TF et al. | Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. | 2011 | Scand. J. Infect. Dis. | pmid:21534891 |
Montana M et al. | Safety review: squalene and thimerosal in vaccines. | 2010 Nov-Dec | Therapie | pmid:21176760 |
Bhilwade HN et al. | Squalene as novel food factor. | 2010 | Curr Pharm Biotechnol | pmid:20874681 |
Iannitti T and Palmieri B | An update on the therapeutic role of alkylglycerols. | 2010 | Mar Drugs | pmid:20948908 |
Lippi G et al. | Vaccination, squalene and anti-squalene antibodies: facts or fiction? | 2010 | Eur. J. Intern. Med. | pmid:20206873 |
Barnett SW et al. | Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. | 2010 | J. Virol. | pmid:20392857 |
Caron J et al. | Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues. | 2010 | Bioorg. Med. Chem. Lett. | pmid:20363623 |
Xiong Z et al. | A short total synthesis of (+)-omaezakianol via an epoxide-initiated cationic cascade reaction. | 2010 | Org. Lett. | pmid:20218639 |
Durando P et al. | MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. | 2010 | Expert Opin Biol Ther | pmid:20218923 |
Taramino S et al. | Interactions of oxidosqualene cyclase (Erg7p) with 3-keto reductase (Erg27p) and other enzymes of sterol biosynthesis in yeast. | 2010 | Biochim. Biophys. Acta | pmid:19879375 |
van Himbergen TM et al. | Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. | 2010 | Arterioscler. Thromb. Vasc. Biol. | pmid:19834104 |
Keitel W et al. | Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. | 2010 | Vaccine | pmid:19835829 |
Dosio F et al. | Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation. | 2010 | Bioconjug. Chem. | pmid:20597546 |
Sarpietro MG et al. | Interaction of acyclovir and its squalenoyl-acyclovir prodrug with DMPC in monolayers at the air/water interface. | 2010 | Int J Pharm | pmid:20635474 |
Wohlrab J et al. | Interaction of epicutaneously applied lipids with stratum corneum depends on the presence of either emulsifiers or hydrogenated phosphatidylcholine. | 2010 | Skin Pharmacol Physiol | pmid:20523109 |
Koohang A et al. | Enantioselective inhibition of squalene synthase by aziridine analogues of presqualene diphosphate. | 2010 | J. Org. Chem. | pmid:20545375 |
Camin F et al. | Stable isotope ratios of carbon and hydrogen to distinguish olive oil from shark squalene-squalane. | 2010 | Rapid Commun. Mass Spectrom. | pmid:20499327 |
Mantzouridou F and Tsimidou MZ | Observations on squalene accumulation in Saccharomyces cerevisiae due to the manipulation of HMG2 and ERG6. | 2010 | FEMS Yeast Res. | pmid:20550581 |
Van Damme P et al. | Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. | 2010 | BMC Infect. Dis. | pmid:20504306 |
Waddington CS et al. | Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. | 2010 | BMJ | pmid:20508026 |
Beck F et al. | Queries about vaccines containing squalene. | 2010 | Immunol. Cell Biol. | pmid:20157330 |
Gerpe A et al. | Naftifine-analogues as anti-Trypanosoma cruzi agents. | 2010 | Eur J Med Chem | pmid:20163894 |
Narayan BH et al. | Modulation of doxorubicin-induced genotoxicity by squalene in Balb/c mice. | 2010 | Food Funct | pmid:21776469 |
Ali NA et al. | Essential oil composition of leaves of Stachys yemenensis obtained by supercritical COâ‚‚. | 2010 | Nat. Prod. Res. | pmid:21104527 |
Walker WT and Faust SN | Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. | 2010 | Expert Rev Vaccines | pmid:21105775 |
El Sahly H | MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. | 2010 | Expert Rev Vaccines | pmid:20923265 |
Waddington C et al. | Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. | 2010 | Health Technol Assess | pmid:20923610 |